Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 10/20 | 0.62 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.62 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | PIK3R2 | O00459 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12105287 | 0.91 | PIK3CG (0.64) | PIK3CGPIK3CDPIK3CBPOLBRECQL | |
| SCHEMBL1300328 | 0.91 | PIK3CG (0.64) | PIK3CGPIK3CDPIK3CBPOLBRECQL | |
| SCHEMBL369837 | 0.89 | PIK3CG (0.77) | PIK3CGPIK3CDPIK3CBPOLBRECQL | |
| SCHEMBL19198778 | 0.89 | PIK3CG (0.62) | PIK3CGPIK3CDPIK3CBPOLBRECQL | |
| SCHEMBL1299798 | 0.88 | PIK3CG (0.61) | PIK3CGPIK3CDPIK3CBPOLBRECQL | |
| SCHEMBL12264522 | 0.88 | PIK3CG (0.56) | PIK3CGPIK3CDPIK3CBPOLBRECQL | |
| SCHEMBL1497348 | 0.88 | PIK3CG (0.56) | PIK3CGPIK3CDPIK3CBPOLBRECQL | |
| SCHEMBL1300314 | 0.88 | PIK3CG (0.60) | PIK3CGPIK3CDPIK3CBPOLBRECQL | |
| SCHEMBL19198821 | 0.87 | PIK3CG (0.59) | PIK3CGPIK3CDPIK3CBPOLBRECQL | |
| SCHEMBL1299500 | 0.86 | PIK3CG (0.58) | PIK3CGPIK3CDPIK3CBPOLBRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2475375-A2 | PI3 KINASE INHIBITORS AND USES THEREOF | Avila Therapeutics, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| WO-2011031896-A2 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | PIK3CA, PIK3CB, PIK3C2B | PIK3CG 6/4885PIK3CD 5/4885PIK3CB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.